Danaher (NYSE:DHR) Releases Earnings Results, Beats Expectations By $0.15 EPS

Danaher (NYSE:DHR) released its quarterly earnings results on Tuesday. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15, Briefing.com reports. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.05 EPS.

Danaher Price Performance

Shares of DHR stock opened at $274.10 on Friday. Danaher has a 1 year low of $182.09 and a 1 year high of $276.31. The firm’s 50 day moving average is $254.99 and its 200-day moving average is $248.82. The firm has a market capitalization of $197.96 billion, a price-to-earnings ratio of 45.78, a PEG ratio of 4.11 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.51 and a debt-to-equity ratio of 0.33.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. Danaher’s payout ratio is 18.31%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and upped their price target for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. Royal Bank of Canada upped their price target on Danaher from $297.00 to $300.00 and gave the company an “outperform” rating in a research report on Wednesday. Jefferies Financial Group began coverage on Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective for the company. Robert W. Baird increased their price objective on Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, Bank of America increased their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Wednesday. Six equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $276.88.

Insider Transactions at Danaher

In related news, Director Alan G. Spoon sold 708 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the transaction, the director now directly owns 116,202 shares in the company, valued at $28,304,483.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Danaher news, CEO Rainer Blair sold 19,085 shares of the stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $255.00, for a total value of $4,866,675.00. Following the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at $29,578,725. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the transaction, the director now directly owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The disclosure for this sale can be found here. Over the last three months, insiders have sold 75,175 shares of company stock worth $19,161,154. Corporate insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.